In gathering data on potential COVID-19 therapeutics, clinical trial networks can accomplish what individual study sites are unable to do, Mark McClellan, director of the Duke-Margolis Center for Health Policy at Duke University, said.
Speaking at the Drug Information Association's virtual meeting 17 June, McClellan noted that in the early days of the pandemic,...